

Journal of Visualized Experiments

In Vitro Assay to Study Tumor-Macrophage Interaction

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59907R2
Full Title:	In Vitro Assay to Study Tumor-Macrophage Interaction
Keywords:	Macrophage, tumor, conditioned medium, the tumor microenvironment, glioblastoma, the epidermal growth factor receptor
Corresponding Author:	Zhenyi An UNITED STATES
Corresponding Author's Institution:	
Corresponding Author E-Mail:	anzhenyi@gmail.com
Order of Authors:	Zhenyi An William A. Weiss
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	San Francisco/CA USA

TITLE:

In Vitro Assay to Study Tumor-Macrophage Interaction

AUTHORS AND AFFILIATIONS:

Zhenyi An¹, William A. Weiss^{1,2,3}

¹Department of Neurology, University of California, San Francisco, CA, USA

²Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA

³Departments of Pediatrics and Neurological Surgery, University of California, San Francisco, CA, USA

Email addresses of co-authors:

Zhenyi An (zhenyi.an@ucsf.edu)

Corresponding author:

William A. Weiss (william.weiss@ucsf.edu)

KEYWORDS:

macrophage, tumor, conditioned medium, the tumor microenvironment, glioblastoma, the epidermal growth factor receptor

SUMMARY:

This article represents a useful in vitro assay to evaluate the capability of conditioned medium from tumor cells to attract macrophages.

ABSTRACT:

Tumor associated macrophages (TAMs) account for a large percentage of cells in the tumor mass for different types of cancers. Glioblastoma (GBM), a malignant brain tumor with no cure, has up to a half the tumor mass TAMs. TAMs can be pro-tumoral or anti-tumoral, depending on the activation of specific genes in the cells. Genetic mutations in the tumors, through regulating cytokine expression, can affect recruitment of TAMs to the tumor microenvironment. Here, we describe a quantitative cell-based assay to assess macrophage recruitment by the conditioned medium from the tumor cells. This assay uses the human macrophage cell line MV-4-11 to study macrophage attraction by the conditioned medium from glioblastoma, allowing for high reproducibility and low variability. Data generated with this assay can contribute to a better understanding of the interaction between the tumor and the tumor microenvironment. Similar assay can be used to assess interaction between the tumor cells and other immune cells, including T cells and natural killer (NK) cells.

INTRODUCTION:

Macrophages are immune cells with high phenotypic and functional heterogeneity¹. They play important roles in the host defense systems, tissue repair, development and tumor progression¹. TAMs are macrophages in the microenvironment of solid tumors. Certain TAMs can promote

tumor growth through inhibiting T cell-mediated cytotoxic activity, modulating the tumor microenvironment (TME), promoting angiogenesis, invasion and metastasis²⁻⁵. TAMs are among the most abundant cell types in the TME and higher number of TAMs generally correlates with worse patient survival in many types of solid tumors⁶. The distinct genetic signatures of the tumor cells affect their ability to recruit macrophages. In GBM, an aggressive brain tumor with no cure, macrophages can represent up to a half of the tumor mass⁷. Co-amplification of the epidermal growth factor receptor (*EGFR*) and its truncation mutant *EGFRvIII* is frequently observed in GBM, which confers tumor growth advantages⁸. Cells co-expressing EGFR and EGFRvIII attract more macrophages compared to cells expressing EGFR or EGFRvIII singly⁷.

Chemokines are a family of small cytokines that play significant roles in regulating immune composition in the TME^{6,9}. Human cells express more than 50 cytokines¹⁰. Immune infiltration in the tumors is largely realized by the interaction between cytokines and cytokine receptors¹¹. Each type of immune cells expresses distinct chemokine receptors/chemokines and can be recruited by cells secreting specific chemokines/chemokine receptors¹². Cancer cells can increase expression of certain chemokines to recruit immune cells such as TAMs, regulatory T cells and myeloid-derived suppressor cells (MDSCs)⁶. Blockade of specific chemokine secreted by the tumors can be a promising way in inhibiting infiltration of immune cells into the tumor mass.

Here, we describe a protocol that allows in vitro evaluation of tumor-macrophage interaction, using conditioned media from the tumor cells containing chemokines and macrophage cell lines.

PROTOCOL:

1. Medium preparation

1.1. Preparation of the serum-free stem cell medium

1.1.1. Thaw the 50x B27 supplement, the epidermal growth factor (EGF, 20 µg/mL in 10 mM acetic acid with 0.1% BSA), and the fibroblast growth factor (FGF, 20 µg/mL in 10 mM acetic acid with 0.1% BSA).

1.1.2. Add 500 µL of EGF (final concentration 20 ng/mL), 500 µL of FGF (final concentration 20 ng/mL), 10 mL of 50x B27 to 500 mL of Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) and 5 mL of 100 x penicillin/streptomycin (Pen Strep). Invert the bottle 4-6 times to mix, filter sterilize through a 500 mL 0.1 µm filtration cup. Mark the bottle and store at 4 °C.

NOTE: The medium is good to use for up to a month at 4 °C.

1.2. Prepare the MV-4-11 culture medium: Add 50 mL of fetal bovine serum (FBS) to 500 mL of Iscove's Modified Dulbecco's Medium (IMDM). Invert the bottle 4-6 times to mix, filter sterilize through a 500 mL 0.1 µm filtration cup. Mark the bottle and store at 4 °C.

NOTE: The medium is good to use for up to a month at 4 °C.

1.3. Prepare the tumor cell maintenance medium: Add 50 mL of FBS to 500 mL of Dulbecco's Modified Eagle Medium (DMEM). Invert the bottle 4-6 times to mix, filter sterilize through a 500 mL 0.1 µm filtration cup. Mark the bottle and store at 4 °C.

NOTE: The medium is good to use for up to a month at 4 °C.

2. Cell preparation

Day 1:

2.1. Thawing tumor cells

2.1.1. Warm up the tumor cell maintenance medium (as described in step 1.3) at a 37 °C water bath for 20 min.

2.1.2. Take the frozen U87, U87:EGFR, U87:EGFRvIII and U87:EGFR+EGFRvIII cells from the liquid nitrogen tank. Thaw the cells at the 37 °C water bath for 2 min.

CAUTION: Be careful when taking the cells from the liquid nitrogen tank. Wear gloves with thermal protection and safety goggles as needed.

2.1.3. Spray the tissue culture hood surface with 70% ethanol and wipe off 70% ethanol on the surface with paper towels.

2.1.4. Spray the cryogenic vials containing cells and the medium bottle with 70% ethanol, wipe off 70% ethanol on the surface with paper towels, and bring them into the tissue culture hood.

2.1.5. Pipette 5 mL of tumor cell maintenance medium into a 15 mL sterile centrifuge tube. Invert the tube containing tumor cells 4-6 times to mix. Pipette all the cells into the 15 mL centrifuge tube. Invert the centrifuge tube 4-6 times to mix.

2.1.6. Centrifuge the cells at 200 x g for 5min at 4 °C. Aspirate the supernatant.

2.1.7. Wash the cells with 10 mL of phosphate buffered saline (PBS). Centrifuge the cells at 200 x g for 5min at 4 °C. Aspirate the supernatant.

2.1.8. Resuspend the cells in 12 mL of tumor cell maintenance medium (as described in step 1.3). Pipette up and down 3-5 times to mix. Transfer the cells into a T75 cell culture flask.

2.1.9. Grow the cells in a 37 °C incubator with 5% CO₂. Put the tumor cell maintenance medium back to the 4 °C fridge.

Day 2:

2.2. Check the cells under the microscope. Change the medium if needed. Cells should grow in a monolayer in culture.

Day 3:

2.3. Thawing MV-4-11 cells

2.3.1. Warm up the MV-4-11 culture medium (as described in step 1.2) at a 37 °C water bath for 20 min.

NOTE: MV-4-11 can be changed to primary macrophages or other macrophage cell lines, depending on the need of the specific study.

2.3.2. Take the frozen MV-4-11 cells from the liquid nitrogen tank. Thaw the cells at a 37 °C water bath for 2 min.

CAUTION: Be careful when taking the cells from the liquid nitrogen tank. Wear gloves with thermal protection and safety goggles as needed.

2.3.3. Spray the tissue culture hood surface with 70% ethanol and wipe off 70% ethanol on the surface with paper towels.

2.3.4. Spray the cryogenic vials containing cells and the medium bottle with 70% ethanol, wipe off 70% ethanol on the surface with paper towels, and bring them into the tissue culture hood.

2.3.5. Pipette 5 mL of MV-4-11 culture medium (as described in step 1.2) into a 15 mL sterile centrifuge tube. Invert the tube containing tumor cells 4-6 times to mix. Pipette all the cells into the 15 mL centrifuge tube. Invert the centrifuge tube 4-6 times to mix.

2.3.6. Centrifuge the cells at 200 x *g* for 5 min at 4 °C. Aspirate the supernatant.

2.3.7. Wash the cells in 10 mL of PBS and centrifuge the cells at 200 x *g* for 5 min at 4 °C. Aspirate the supernatant.

2.3.8. Resuspend the cells in 12 mL of MV-4-11 culture medium (as described in step 1.2). Gently pipette up and down 3-5 times to mix. Transfer the cells into a T75 cell culture flask.

2.3.9. Grow the cells in a 37 °C incubator with 5% CO₂.

2.4. Splitting tumor cells

2.4.1. Warm up the serum-free stem cell medium (as described in step 1.1) at a 37 °C water bath for 20 min.

2.4.2. Spray the tissue culture hood surface with 70% ethanol and wipe off 70% ethanol on the surface with paper towels. Take the cell detachment solution from the fridge. Spray the medium and cell detachment solution bottles with 70% ethanol, wipe off 70% ethanol on the surface with paper towels and bring them into the tissue culture hood.

NOTE: Do not pre-warm the accutase cell detachment solution.

2.4.3. Transfer the tumor cell culture from the incubator into the tissue culture hood. Aspirate the medium, add 2 mL of cell detachment solution into the flask.

NOTE: Rinsing with PBS before adding accutase is optional here.

2.4.4. Set the flask in the hood. Check if the tumor cells round up every minute. Once the tumor cells round up, gently tap the side of the flask to help the cells detach from the flask.

2.4.5. Pipette 8 mL of serum-free stem cell medium into the flask, pipette up and down 3 times to mix, and transfer the cells into a 15 mL sterile centrifuge tube. Centrifuge the cells at 200 x g for 5 min at 4 °C. Aspirate the supernatant.

2.4.6. Wash the cells in 10 mL of PBS. Pipette up and down 3-5 times to mix. Centrifuge the cells at 200 x g for 5 min at 4 °C. Aspirate the supernatant.

NOTE: This step is optional.

2.4.7. Resuspend the cells in 10 mL of serum-free stem cell medium (as described in step 1.1). Pipette up and down 3-5 times to mix. Take 10 µL of the cells and mix with 10 µL of Trypan Blue solution. Pipette 10 µL of the mixture into the counting slide, quantify living cell number using an automatic cell counter.

2.4.8. Adjust the cell density to 2.5×10^5 cells/mL with serum-free stem cell medium (as described in step 1.1), and seed 2 mL of the cells into each well of a 6-well cell-culture plate. For each type of cells, seed 3 wells (triplicate sample). At the same time, prepare 6 wells with 2 mL of serum-free stem cell medium only (no cells).

NOTE: These samples will be used: 1) as negative controls and 2) for adjusting conditioned medium volume based on cell numbers.

2.4.9. Put the 6-well plates in a 37 °C incubator with 5% CO₂. Allow the cells to grow for 24 h.

3. In vitro macrophage attraction assay

3.1. Preparation of conditioned media

3.1.1. Warm up the tumor cell maintenance medium (as described in step 1.3) at a 37 °C water bath for 20 min.

3.1.2. Spray the tissue culture hood surface with 70% ethanol and wipe off 70% ethanol on the surface with paper towels. Take the cell detachment solution from the fridge. Spray the bottles of the medium and the cell detachment solution with 70% ethanol, wipe off 70% ethanol on the surface with paper towels and bring them into the tissue culture hood.

3.1.3. Take the 6-well plates out from the incubator. Carefully pipette the conditioned media into 15 mL sterile centrifuge tubes. Put the tubes on ice. Pipette the media in the “media only” well into a separate 15 mL sterile centrifuge tube.

3.1.4. Add 0.5 mL of cell detachment solution into each well of the 6-well plate. Check if the tumor cells round up every minute. Once the tumor cells round up, gently tap the side of the plate to help the cells detach.

3.1.5. Pipette 2.5 mL of tumor cell maintenance medium into the well, pipette up and down 3 times to mix and transfer the cells into a 15 mL sterile centrifuge tube. Take 10 µL of the cells and mix with 10 µL of Trypan Blue solution. Pipette 10 µL of the mixture into the counting slide and quantify the number of living cells using an automatic cell counter.

3.1.6. Adjust the volume of the conditioned media according to cell number using the serum free stem cell medium (37 °C incubation overnight). For example, if Well A has 3x as many live cells as the well with the least number of cells, dilute its conditioned media 1:3. This step is used to control difference caused by cell proliferation rate.

NOTE: The reason to use serum free stem cell medium with 37 °C incubation overnight is to control the possible change in the media with prolonged 37 °C exposure.

3.1.7. Filter the conditioned media through 0.45 µm filters. Put the conditioned media on ice.

NOTE: This step removes cells and cell debris in the conditioned media.

3.2. Preparation of MV-4-11 cells

3.2.1. Warm up the IMDM medium (without FBS) at a 37 °C water bath for 20 min.

3.2.2. Spray the tissue culture hood surface with 70% ethanol and wipe off 70% ethanol on the surface with paper towels. Spray the medium bottle with 70% ethanol, wipe off 70% ethanol on the surface with paper towels and bring them into the tissue culture hood.

3.2.3. Take the flask of MV-4-11 cells into the tissue culture hood. Pipette 10 mL of cells into a 15 mL sterile centrifuge tube. Take 10 µL of cells and mix with 10 µL of Trypan Blue solution. Pipette 10 µL of the mixture into the counting slide and quantify the number of living cells using

an automatic cell counter. Centrifuge the cells at 200 x *g* for 5min at 4 °C. Aspirate the supernatant.

3.2.4. Wash the cells with 10 mL of PBS and centrifuge the cells at 200 x *g* for 5 min at 4 °C. Aspirate the supernatant.

3.2.5. Resuspend the cells in IMDM medium (without FBS) for a final cell density of 1×10^6 cells/mL.

NOTE: The cell number of macrophages used here can be adjusted.

3.3. Transwell assay

NOTE: For this step, use a cell migration assay kit or purchase the reagents and insert separately. For MV-4-11 cells, choose Transwell inserts with 5 μ m pore size. To detect macrophage migration, directly quantify the number of macrophages in the lower chamber or use colorimetric/fluorimetric methods. Here, we demonstrate the assay using the colorimetric method.

3.3.1. Bring the 24-well plate, the insert and the reagents to room temperature.

3.3.2. Add 250 μ L of MV-4-11 cells prepared above into each insert.

3.3.3. Add 400 μ L of conditioned medium/medium only (with overnight incubation at 37 °C, these samples serve as the negative control) to the lower chambers of the 24-well plate. For each tumor line or control, use triplicate samples. Avoid bubbles between the insert and the conditioned medium. Bubbles will inhibit macrophages from migrating to the bottom wells.

3.3.4. Incubate the plates in a 37 °C incubator with 5% CO₂ for 4 h.

NOTE: The incubation time can be adjusted. Cells migrating into the lower chambers can be seen under the microscope.

3.3.5. Gently tap the insert on the inner wall of the same well and discard the insert. As MV-4-11 cells grow in suspension, cell detachment solution or trypsin treatment is not needed here.

3.3.6. Gently pipette the cells in the wells up and down 3 times to mix. Transfer 225 μ L of cell suspension to a black-walled 96-well plate suitable for fluorescent measurement.

3.3.7. Dilute the CyQuant dye 1:75 with 4x lysis buffer. Vortex briefly and spin down the solution. Add 75 μ L of solution to each well of the 96-well plate. Incubate 15 min at room temperature.

3.3.8. Read fluorescence using the 480/520 nm filter set with a fluorescence plate reader.

3.3.9. Analyze data by subtracting the blank and normalizing to the control tumor cell line.

REPRESENTATIVE RESULTS:

The results are usually showed via bar graphs (example shown in **Figure 1**). Samples with high 480/520 values indicate that the conditioned media has high capacity to recruit macrophages. Depending on experimental need, additional controls can be included. For example, one can use neutralizing antibodies to treat the conditioned media to abolish the macrophage chemotaxis, and perform the same assay. One can also add extra chemokines (i.e., CCL2) to the conditioned media, which serves as a positive control.

FIGURE AND TABLE LEGENDS:

Figure 1. Conditioned media from U87 cells co-expressing EGFR and EGFRvIII attract more macrophages than U87 cells expressing a control vector, or EGFR/EGFRvIII singly. This figure has been modified from An, et al.⁷.

DISCUSSION:

In this protocol, there are several key steps: 1) selection of the Transwell insert. For the MV-4-11 cell line, 5 μ m Transwell inserts work well. However, for other cell lines such as the commonly used monocyte cell line THP-1, a different pore size might work better. 2) As different cell lines grow at different speeds, it is important to adjust the volume of the conditioned media according to cell numbers. For this purpose, cell-free media incubated under the same experimental conditions can be used to dilute the conditioned media. 3) FBS contains cytokines. It is important to use serum-free medium to seed MV-4-11 cells in the upper chamber. If FBS is used here, sometimes cell migration cannot be observed.

Researchers can modify this assay for different applications. For example, other tumor cells, either primary patient-derived xenograft culture, or mouse cells can substitute the brain tumor cell line used in the above-mentioned example. The macrophage cell line can be substituted by primary macrophages or monocytes from patients or mice depending on the specific need. One important point is that the researchers need to select cells from the same species to ensure best result. Although the macrophage chemotaxis pathway is highly conserved, the variation of protein sequence of structure between different species may add layers of complication to interpret experimental results.

TAMs are attracting increasingly more attention in cancer immunology^{13,14}. How different genetic changes in the tumors affect recruitment of TAMs and other immune cells in the tumor microenvironment still awaits further studies. By changing pore sizes of the Transwell inserts, this assay can be used to study interaction between tumor and other immune cells such as T cells and NK cells. One advantage of using the Transwell assay to evaluate tumor-immune interaction is that it is easy to demonstrate how specific oncogenes/mutations affect recruitment of a certain type of immune cells. Moreover, this assay is easy to scale-up for genome-wide screens. This assay opens up additional possibilities for researchers to study tumor-immune cell interactions. Additionally, this assay can be used to study how the conditioned media from tumor cells affect

the transcription profile of the macrophages/other immune cells.

All assays have their limitations. For this assay, the conditioned medium is from tumor cells cultured in vitro. The secreted chemokines here might be different from those secreted by tumors grown in vivo. Additionally, the macrophage cell line is different from tumor infiltrating macrophages, which are more phenotypically and transcriptionally diverse. Therefore, further confirmation of the in vitro findings using other in vitro and in vivo methods is necessary.

ACKNOWLEDGMENTS:

Grant Support: Z. An received support from Alex's Lemonade Stand Foundation, American Brain Tumor Association, NIH T32CA108462 and Program for Breakthrough Biomedical Research, which is partially funded by the Sandler Foundation. W. Weiss was supported by NIH grants R01CA221969, R01NS091620, P50CA097257, U01CA217864, P30CA82103; the Samuel G. Waxman Cancer Research Foundation; and the Evelyn and Mattie Anderson Chair.


DISCLOSURES:

William A. Weiss is a co-founder of StemSynergy Therapeutics. Zhenyi An has nothing to disclose.

REFERENCES:

- 1 Liu, Y. & Cao, X. The origin and function of tumor-associated macrophages. *Cellular & Molecular Immunology*. **12** (1), 1-4, doi:10.1038/cmi.2014.83, (2015).
- 2 Riabov, V. *et al.* Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. *Frontiers in Physiology*. **5** 75, doi:10.3389/fphys.2014.00075, (2014).
- 3 Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet? *Science*. **339** (6117), 286-291, doi:10.1126/science.1232227, (2013).
- 4 Tsukamoto, H. *et al.* Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. *Cancer Research*. **78** (17), 5011-5022, doi:10.1158/0008-5472.CAN-18-0118, (2018).
- 5 Borgoni, S. *et al.* Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. *Oncoimmunology*. **7** (2), e1393596, doi:10.1080/2162402X.2017.1393596, (2018).
- 6 Argyle, D. & Kitamura, T. Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors. *Frontiers in Immunology*. **9** 2629, doi:10.3389/fimmu.2018.02629, (2018).
- 7 An, Z. *et al.* EGFR cooperates with EGFRvIII to recruit macrophages in glioblastoma. *Cancer Research*. doi:10.1158/0008-5472.CAN-17-3551, (2018).
- 8 Fan, Q. W. *et al.* EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. *Cancer Cell*. **24** (4), 438-449, doi:10.1016/j.ccr.2013.09.004, (2013).
- 9 Jacquelot, N., Duong, C. P. M., Belz, G. T. & Zitvogel, L. Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. *Frontiers in Immunology*. **9** 2480, doi:10.3389/fimmu.2018.02480, (2018).
- 10 Arimont, M. *et al.* Structural Analysis of Chemokine Receptor-Ligand Interactions. *Journal*

- of Medicinal Chemistry*. **60** (12), 4735-4779, doi:10.1021/acs.jmedchem.6b01309, (2017).
- 11 Turner, M. D., Nedjai, B., Hurst, T. & Pennington, D. J. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. *Biochimica et Biophysica Acta*. **1843** (11), 2563-2582, doi:10.1016/j.bbamcr.2014.05.014, (2014).
- 12 Sokol, C. L. & Luster, A. D. The chemokine system in innate immunity. *Cold Spring Harbor Perspectives in Biology*. **7** (5), doi:10.1101/cshperspect.a016303, (2015).
- 13 Pathria, P., Louis, T. L. & Varner, J. A. Targeting Tumor-Associated Macrophages in Cancer. *Trends in Immunology*. **40** (4), 310-327, doi:10.1016/j.it.2019.02.003, (2019).
- 14 Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. *Nature Reviews Clinical Oncology*. **14** (7), 399-416, doi:10.1038/nrclinonc.2016.217, (2017).



Name of Material/ Equipment	Company	Catalog Number	Comments/Description
0.1 µm filtration cup	Thermo fisher	566-0010	
0.45 µm filter unit	Millipore	SLHA033SS	
10 mL serological pipettes	Olympus plastics	12-104	
15mL sterile centrifuge tubes	Olympus plastics	28-103	
1 mL pipette tip	ART molecular bioproducts	2779-RI	
2 mL aspirating pipet	Falcon	357558	
24-well plate	Millipore	ECM507	Part of ECM507, or can be purchased separately
4x lysis buffer	Millipore	ECM507	Part of ECM507, or can be purchased separately
5 µm Transwell insert	Millipore	ECM507	Part of ECM507, or can be purchased separately
75cm ² flask	Corning	430641U	
Accutase	Innovative cell technologies	AT-104	
B27	Gibco	12587-010	
CyQuant Dye	Millipore	ECM507	Part of ECM507, or can be purchased separately
DMEM	Gibco	11965-092	
DMEM:F12	Gibco	10565-018	
EGF	Peprtech	AF-100-15	
FBS	Gibco	26140	
FGF	Peprtech	100-18B	
IMDM	Gibco	12440-053	
PBS	Gibco	14190-144	
Pen Strep	Gibco	15140-122	
Trypan blue	Biorad	1450021	



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Author(s):

Zhenyi An and William A. Weiss

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	William. A. Weiss	
Department:	Departments of Pediatrics and Neurological Surgery	
Institution:	UCSF	
Title:	Professor	
Signature:		Date: 12/13/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

April 6, 2018

MS ID#: JoVE59907

Title: In Vitro Assay to Study Tumor-Macrophage Interaction

Dear Dr. Wu,

Thank you for giving us the opportunity to submit a revised version of the manuscript entitled "In Vitro Assay to Study Tumor-Macrophage Interaction"(JoVE59907). We have addressed the concerns. A point-by-point response is given below:

Editorial comments:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

We have thoroughly proofread the manuscript and corrected all spelling and grammar issues we discovered.

2. JoVE cannot publish manuscripts containing commercial language. This includes company names of an instrument or reagent, e.g., Millipore, CyQUANT, etc. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents.

We have eliminated the company names.

3. Please define all abbreviations before use, e.g., FBS, EGF, BSA, FGF, PBS, etc.

We have defined those abbreviations.

4. Please use greek characters for SI unit prefixed, e.g. use ‘ μ g’ instead of ‘ug’.

We have corrected those characters.

5. Step 2.1.8: What’s the composition of tumor cell maintenance medium?

To make it clear, we added “as described in 1.3”.

6. Please do not abbreviate journal titles for references.

We have included the full names for those journal titles.



AACR Journals Editors' Picks

Now featured in *Cancer Research Catalyst*

[READ THE BLOG](#)



PUBLICATIONS

Copyright, Permissions, and Access

VISIT OUR
**AUTHOR SERVICES
CENTER**

This section provides an overview of the copyright and permissions policies of the AACR journals with guidance on published article reuse by authors and others. The final typeset version of every published article is freely available to all readers 12 months after publication. Alternatively, authors may choose to pay an AuthorChoice fee to make their article freely available immediately. The AACR also assists authors in fulfilling funder Open Access mandates by depositing the accepted version of their article in a designated public repository within the required time period.

Copyright and Permissions

Copyright Transfer

As a not-for-profit organization incorporated in the United States, the AACR adheres to U.S. copyright law (PL 94-553), which became effective January 1, 1978. The law stipulates that copyright for works is vested in the author from the moment of creation and remains the property of the author until legally transferred. Authors who wish to publish articles and other material in AACR journals must formally transfer copyright to AACR. The copyright transfer form must be signed by all authors before AACR can proceed with publication.

After the editor has made an initial decision about the potential suitability of a manuscript for publication (i.e., requesting revisions for or provisionally accepting it), all authors on the manuscript will receive an email requesting that they complete an online copyright transfer agreement through the SmartSubmit system. If an author is unable to complete the copyright transfer agreement online, the [Copyright Transfer Form](#) (PDF) can be downloaded, signed, and returned via the email address or fax number noted on the form. The AACR journals will not

Information for
Authors »

Select a Journal »

Editorial Process »

Editorial Policies »

Article Style
and Formats »

Copyright, Permissions,
and Access

**Copyright and
Permissions**

Copyright transfer
Reuse of materials by
authors
Reuse of materials by
others

**Free Access and Article
Archiving**

Archiving Mandates
AuthorChoice

publish a manuscript unless forms have been properly completed and returned by ALL authors.

NOTE: If using the writable PDF form linked to above, authors must either include a handwritten signature (either by signing the electronic document using a stylus or by printing and scanning a hand-signed document) or they will need to validate the document with a digital signature (an electronic signature used to authenticate the identity of the signer of a document).

In conveying copyright, it is understood that the authors have not published this material elsewhere, either in whole or in part (except in abbreviated form as a preliminary communication or abstract) and that they have neither concluded previous negotiations nor initiated pending negotiations for copyright of this material.

The duly authorized agent of a commercial firm or commissioning organization must sign the AACR copyright transfer form if the author prepared the article as part of his or her official duties as an employee.

The U.S. government has determined that it has a nonexclusive right to publish or republish material developed from work performed by federal employees. Because the federal government does not recognize private copyright for work performed by its employees as part of their official duties, the journal will accept manuscripts from government laboratories without copyright transfer, provided that the authors abide by the same provisions required of other authors.

Article Reuse by Authors

Authors of articles published in AACR journals are permitted to use their article or parts of their article in the following ways without requesting permission from the AACR. All such uses must include appropriate attribution to the original AACR publication. Authors may do the following as applicable:

1. Reproduce parts of their article, including figures and tables, in books, reviews, or subsequent research articles they write;
2. Use parts of their article in presentations, including figures downloaded into PowerPoint, which can be done directly from the journal's website;
3. Post the accepted version of their article (after revisions resulting from peer review, but before editing and formatting) on their institutional website, if this is required by their institution. The version on the institutional repository must contain a link to the final, published version of the article on the AACR journal website so that

Publication Fees and Reprints »

FAQ »

any subsequent corrections to the published record will continue to be available to the broadest readership. The posted version may be released publicly (made open to anyone) 12 months after its publication in the journal;

4. Submit a copy of the article to a doctoral candidate's university in support of a doctoral thesis or dissertation.

Article Reuse by Others

Third parties or individuals who are seeking permission to copy, reproduce, or republish content from an AACR journal and who are not the author of that content may use the Copyright Clearance Center's Rightslink® service to request permission to reuse identified content. Please see **Third Party Permission and Reprints** for detailed instructions on how to submit a request.

Free Access and Article Archiving

All final typeset articles in AACR journals are made free (open) to anyone to read or use (subject to the conditions listed above) 12 months after the original online publication. In addition, the AACR provides many countries in the developing world with immediate free access to all AACR journals through the HINARI program. Select content will sometimes be made freely available immediately upon publication.

Archiving Mandates

The AACR can assist authors in meeting their funders' archiving mandates. Authors of articles published in AACR journals can elect to have the AACR deposit their accepted manuscripts to PubMed Central (PMC) or Europe PMC, thereby meeting the archiving and release date requirements of the following funding agencies and others:

- National Institutes of Health
- Howard Hughes Medical Institute
- Cancer Research UK
- Wellcome Trust
- Medical Research Council

When submitting a revised version of their manuscript, the corresponding author is asked to indicate whether the accepted version of their manuscript should be deposited in PMC or Europe PMC on their behalf, or if they will instead deposit the accepted version themselves. Authors are

NOT asked to provide funding information or choose a deposition option at initial submission.

If the author chooses to have the AACR deposit the manuscript for them, the accepted version of the manuscript will be uploaded to the repository upon acceptance, with a release date of 6 months post-publication. Authors will be contacted by the repository for approval of the submission. See the following section for information about the AuthorChoice option, which allows for even earlier release.

Please note that, while the AACR will make repository deposits for authors upon request at the time of manuscript acceptance, it is the author's responsibility to follow up with the repository to ensure that the content is received and released within the funder's specified timeframe. Please note also that the article PMCID number is assigned and provided by NIHMS and Europe PMC and that the AACR journals are unable to assign or provide these numbers to authors. Authors who have questions about their PMCID number should contact the corresponding repository directly at www.nihms.nih.gov or europepmc.org.

AuthorChoice

In addition to providing free online access to the final typeset version of all published articles 12 months after publication, the AACR journals also provide an option for authors to pay an AuthorChoice fee to make their accepted articles freely available online immediately upon publication. This includes OnlineFirst and final typeset article versions. Authors may choose this option during submission of a new or revised manuscript.

AuthorChoice articles are not published under an Open Access license and are therefore generally ineligible for funder reimbursement of the AuthorChoice publication fee. Details on fees are provided in the **Publication Fees** section.

American Association for Cancer Research

615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404

Phone: (215) 440-9300 | **Fax:** (215) 440-9354 | **E-mail:** pubs@aacr.org

[Home](#)

[Alerts](#)

[Privacy Policy](#)



Article Collections

[Focus Selections](#)

[Topical Collections](#)

["Best of" Collection](#)

Info for:

[Authors](#)

[Subscribers](#)

[Advertisers](#)

[Librarians](#)

[Reviewers](#)

AACR Journals

[About AACR Journals](#)

[3rd Party Permissions & Reprints](#)



Copyright © 2019 by the American Association for Cancer Research.